Conditions: Renal Cell Carcinoma
Keywords: renal cell cancer kidney vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor hepatocyte growth factor receptor protein (MET) von Hippel-Lindau gene
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 658
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.

Detailed description:

Arms:
arm 1: Cabozantinib (XL184) 60 mg tablet once daily. arm 2: Everolimus (Afinitor) 10 mg tablet once daily.

Interventions: intervention 1: Cabozantinib tablets intervention 2: Everolimus (Afinitor) tablets
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: